Revenue: Down 27% to $12.2 million in the six months to September 30.
Net loss: $14.5m, improved from a $15.3m loss last year.
Main takeaway: The company is not commenting on whether it needs to raise more capital while it continues to wait for a decision on whether its Cxbladder product will be funded by the US Medicare scheme.
Pacific Edge is not commenting on whether it will need to raise capital soon, instead focusing on potential 2025 catalysts against the ongoing headwind of whether its Cxbladder product will be funded by the US Medicare scheme.
The listed cancer diagnostics company today reported a net loss after tax
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
Revenue: Down 27% to $12.2 million in the six months to September 30.
Net loss: $14.5m, improved from a $15.3m loss last year.
Main takeaway: The company is not commenting on whether it needs to raise more capital while it continues to wait for a decision on whether its Cxbladder product will be funded by the US Medicare scheme.
